Analysis Ocugen’s 2027 Data Crossroads: New Leadership, Fresh Capital, and a Binary Bet on Two Trials
The next twelve months will tell whether Ocugen’s pipeline bets pay off — and the company has just reshuffled its deck ahead of the reveal. Two pivotal readouts anchor the...